Sarepta Therapeutics, Inc. (SRPT)
SRPT moved a median of -0.30% 30 minutes after news, and -0.06% by the close. How SRPT actually reacts to news — the realized, point-in-time move the market made, measured across 1,224 labeled events over the last three years with zero look-ahead.
SRPT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 49% | 1,218 |
| 30-min | -0.30% | 44% | 1,221 |
| 60-min | -0.11% | 48% | 1,221 |
| to close | -0.06% | 49% | 1,178 |
| Middle 50% of SRPT reactions | -1.33% to +1.26% |
|---|---|
| Median reaction (30-min) | -0.30% |
| Measured reactions | 1,224 |
Half of all Sarepta Therapeutics, Inc. news events land between -1.33% and +1.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SRPT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 47 | +0.70% | 51% | +0.61% |
| Analyst downgrades | 78 | +0.21% | 51% | +1.73% |
| Coverage initiations | 45 | -0.27% | 47% | -0.37% |
| Rating reiterations | 220 | -0.21% | 46% | -0.77% |
| Price-target raises | 40 | -0.00% | 48% | -0.76% |
| Price-target cuts | 58 | -0.13% | 45% | +0.65% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how SRPT ranks against every other measured name →
That’s how SRPT usually reacts — get an email when it moves on news →Email me when SRPT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SRPT's baseline. Nothing else.
Recent SRPT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting | Press release | Business Wire | -0.09% | +1.81% | |
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.03% | -3.14% | |
| Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne | Press release | Business Wire | -0.48% | -2.04% | |
| Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress | Press release | Business Wire | +0.00% | +0.97% | |
| Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting | Press release | Business Wire | +1.23% | -1.97% | |
| Form 8-K Sarepta Therapeutics, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +1.23% | -1.97% | |
| Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year | Press release | Business Wire | +0.64% | +6.62% | |
| Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | Business Wire | +0.67% | +2.15% | |
| Form 13F-HR Sarepta Therapeutics, For: Jun 30 | SEC filing · Form 13F-HR | SEC EDGAR | -1.65% | -0.66% | |
| Form 10-Q Sarepta Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.44% | +0.72% | |
| Form 8-K Sarepta Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +1.44% | +0.72% | |
| Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments | Press release | Business Wire | +1.44% | +0.72% | |
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.77% | +0.13% | |
| Form S-8 Sarepta Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.68% | |
| Form 8-K Sarepta Therapeutics, For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | -2.04% | |
| Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer | Press release | Business Wire | +1.94% | -2.04% | |
| Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results | Press release | Business Wire | -0.12% | -2.35% | |
| Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® | Press release | Business Wire | -2.37% | +2.69% | |
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -2.00% | -0.17% | |
| Form 8-K Sarepta Therapeutics, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | -5.06% | |
| Form S-8 Sarepta Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.42% | -5.06% | |
| Sarepta Therapeutics to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.45% | -7.67% | |
| Form 13F-HR Sarepta Therapeutics, For: Mar 31 | SEC filing · Form 13F-HR | SEC EDGAR | -0.21% | -3.31% | |
| Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference | Press release | Business Wire | -0.21% | -3.31% | |
| Form 10-Q Sarepta Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.61% | -5.84% | |
| Form 8-K Sarepta Therapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -5.84% | |
| Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments | Press release | Business Wire | +0.61% | -5.84% | |
| Form ARS Sarepta Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.54% | +3.04% | |
| Form DEF 14A Sarepta Therapeutics, For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.54% | +3.04% | |
| Form DEFA14A Sarepta Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.54% | +3.04% | |
| Sarepta Therapeutics to Announce First Quarter 2026 Financial Results | Press release | Business Wire | -1.28% | -1.99% | |
| When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech | Press release | GlobeNewswire | -1.78% | +0.19% | |
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.28% | +0.96% | |
| Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 | Press release | Business Wire | +7.80% | +20.72% | |
| Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 | Press release | Business Wire | +7.80% | +20.72% | |
| Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® | Press release | Business Wire | -0.89% | -1.71% | |
| Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne | Press release | Business Wire | +0.06% | +0.97% | |
| Form 10-K Sarepta Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.39% | +0.74% | |
| Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program | Press release | Business Wire | -0.50% | -2.39% | |
| Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress | Press release | Business Wire | -2.85% | -1.97% | |
| Form 8-K Sarepta Therapeutics, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.85% | -1.97% | |
| Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments | Press release | Business Wire | -2.85% | -1.97% | |
| Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan | Press release | Business Wire | +2.47% | +2.17% | |
| Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Press release | Business Wire | +2.47% | +2.17% | |
| Form 13F-HR Sarepta Therapeutics, For: Dec 31 | SEC filing · Form 13F-HR | SEC EDGAR | +1.25% | +1.31% | |
| Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results | Press release | Business Wire | -3.54% | -1.80% | |
| Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease | Press release | Business Wire | +1.50% | -2.81% | |
| Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients | Press release | Business Wire | +2.03% | +3.83% | |
| Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy | Press release | Business Wire | +2.03% | +3.83% | |
| Form 8-K Sarepta Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | +0.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SRPT section they belong to.
Where else SRPT is measured.
SRPT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NuVasive, Inc. (NUVA) | 1,226 | +0.03% | 51% |
| DENTSPLY SIRONA Inc. (XRAY) | 1,226 | +0.05% | 52% |
| Orthofix Medical Inc. (OFIX) | 1,217 | +0.06% | 51% |
| IMMUNOMEDICS (IMMU) | 1,213 | -0.08% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sarepta Therapeutics, Inc.'s median reaction calculated?
Every labeled SRPT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,224 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of SRPT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SRPT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.